Looking Into Becton Dickinson's Recent Short Interest - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has risen 16.67% since its last report. The company recently reported that it has 5.48 million shares sold short, which is 1.89% of all regular shares that are available for trading.
Here's Why Becton Dickinson ( BDX ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson ( BDX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
Company News for Aug 8, 2025
Companies in The Business Are: ...
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) EMBC, a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
Becton Dickinson Q3 Beats Estimates On Medical Device Boom - Becton Dickinson ( NYSE:BDX )
Becton Dickinson Q3 EPS of $3.68 beats estimate of $3.41; revenue rose 10.4% to $5.51 billion. BD raises FY25 EPS guidance to $14.30-$14.45 vs consensus of $14.18. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Applovin, Sunrun, Duolingo, Tutor Perini, Installed Building Products And Other Big Stocks Moving Higher On Thursday - AppLovin ( NASDAQ:APP ) , Advanced Micro Devices ( NASDAQ:AMD )
U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday. Shares of Applovin Corp APP rose sharply during Thursday's session following upbeat earnings. AppLovin reported second-quarter revenue of $1.26 billion, missing analyst estimates of $1.31 billion, according ...
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
Becton Dickinson ( BDX ) Surpasses Q3 Earnings and Revenue Estimates
Becton Dickinson (BDX) delivered earnings and revenue surprises of +7.60% and +0.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical ( STAA ) Reports Q2 Loss, Beats Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of +87.50% and +6.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
Curious about Becton Dickinson ( BDX ) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
OraSure Appoints Anne Messing as Chief Commercial Officer
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) ( NASDAQ: OSUR ) , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
OraSure Appoints Anne Messing as Chief Commercial Officer - OraSure Technologies ( NASDAQ:OSUR )
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) OSUR, a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
Earnings Preview: Becton Dickinson ( BDX ) Q3 Earnings Expected to Decline
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
There are no guarantees on Wall Street, especially when it comes to dividends. The board of directors of each company decides on the dividend in private. But income investors can glean some information from past dividend decisions, which is the only information available.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca ( NASDAQ:AZN )
AstraZeneca plans $50 billion in U.S. investment by 2030, including a drug facility in Virginia for its metabolic and weight loss portfolio. Company aims to generate 50% of $80 billion revenue from the U.S. by 2030 with new manufacturing and R&D expansions.
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen ( NASDAQ:BIIB )
Biogen to invest $2 billion more in its RTP manufacturing, adding to $10B already spent in North Carolina. Expansion includes advanced automation, AI integration and multi-platform fill finish capabilities.
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research®
Lewes, Delaware, July 21, 2025 ( GLOBE NEWSWIRE ) -- The Global Sleep Apnea Devices Market Size is projected to grow at a CAGR of 10.42% from 2024 to 2031, according to a new report published by Verified Market Research®.
The Smartest Dividend Stock to Buy With $1,000 Right Now
If you are a dividend investor looking to maximize the income your portfolio generates, you will want to do a deep dive on Universal Health Realty Income Trust ( NYSE: UHT ) . It has a historically high 7.4% dividend yield and a great track record of dividend growth to back it up.
How Do Investors Really Feel About Becton Dickinson? - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has risen 21.62% since its last report. The company recently reported that it has 3.90 million shares sold short, which is 1.35% of all regular shares that are available for trading.
BD Partners With Waters to Build High-Volume Diagnostics Leader
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Monogram Technologies Inc. ( Nasdaq - MGRM ) , Veritex Holdings, Inc. ( Nasdaq - VBTX ) , ESSA Pharma Inc. ( Nasdaq - EPIX ) , Waters Corporation ( NYSE - WAT ) - Huntington Bancshares ( NASDAQ:HBAN )
BALA CYNWYD, Pa., July 14, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Why is Waters Stock Down On Monday? - Becton Dickinson ( NYSE:BDX ) , Waters ( NYSE:WAT )
BD's diagnostics business is projected to generate $3.4 billion in revenue and $925 million in adjusted EBITDA in 2025. Combined company expects $9 billion revenue, $3.3 billion adjusted EBITDA, and 32% margin by 2030. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
One of the good things about the healthcare sector is that most medical care isn't optional. This is the foundation behind the sector, but on that foundation sits the growth opportunity that comes with medical advances.Right now one of the best healthcare stocks to look at is medical device giant ...
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Becton Dickinson Stock: Why It's Best to Avoid For Now - Becton Dickinson ( NYSE:BDX )
Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027.
Infusion Pump Market is expected to generate a revenue of USD 24.09 Billion by 2031, Globally, at 6% CAGR: Verified Market Research®
Lewes, Delaware, June 23, 2025 ( GLOBE NEWSWIRE ) -- The Global Infusion Pump Market Size is projected to grow at a CAGR of 6% from 2024 to 2031, according to a new report published by Verified Market Research®.
New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know - Aon ( NYSE:AON ) , Amazon.com ( NASDAQ:AMZN )
An official report on June 17, 2025 reveals Representative Thomas Kean's recent purchase of Amazon.com AMZN stock, valued between $4,004 and $60,000. The transaction took place on May 8, 2025, as per the June filing. At this time, Amazon.com shares are trading up 1.37% at $217.76.
Hologic Climbs 13% in a Month: How Should You Play the Stock?
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
Henry Schein ( HSIC ) Up 6.5% Since Last Earnings Report: Can It Continue?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Is The Market Feeling About Becton Dickinson? - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has fallen 10.32% since its last report. The company recently reported that it has 3.26 million shares sold short, which is 1.13% of all regular shares that are available for trading.
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Cardiac Marker Market Size Projected to Reach USD 28.27 billion by 2031 at a 13.2% CAGR | The Insight Partners
US & Canada, May 28, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the cardiac marker market is witnessing significant growth owing to the rising prevalence of Cardiovascular diseases ( CVDs ) and growing technological advancements in diagnostic ...
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Becton Dickinson ( NYSE:BDX ) , Accenture ( NYSE:ACN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Snowflake Inc. SNOW price target from $215 to $230. Needham analyst Mike Cikos maintained a ...
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day
PARSIPPANY, N.J., May 22, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta". "The Company" ) ( Nasdaq: EMBC ) , a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation ...
Chronic Total Occlusion Market Size to Surpass USD 42.21 Billion by 2031, Increasing Prevalence of Cardiovascular Diseases Fuels | The Insight Partners
US & Canada, May 20, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the chronic total occlusion market is observing significant growth owing to the increasing prevalence of cardiovascular diseases and strategic initiatives by market players.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 - Sanofi ( NASDAQ:SNY )
Sanofi to invest $20 billion in the US by 2030, boosting R&D and expanding domestic manufacturing capacity. Investment aims to create high-paying jobs and strengthen the US supply chain through partnerships and facility growth.
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of market exclusivity, along with increasing government initiatives to promote the use of generic drugs.
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., May 09, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025.
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Becton Dickinson ( NYSE:BDX ) , Bristol-Myers Squibb ( NYSE:BMY )
FDA conducts 12K domestic inspections yearly, but only 3K abroad-foreign sites flagged for serious issues over twice as often. Johnson & Johnson, Roche, and Novartis plan over $128 billion in combined U.S. investments over the next five years.
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years - Becton Dickinson ( NYSE:BDX )
BDX has dropped 25% since May 2024 vs. S&P 500's 6% and MedTech' Becton Dickinson's organic growth outlook cut to ~3-4%, down from ~5-6% two years ago. Today's manic market swings are creating the perfect setup for Matt's next volatility trade. Get his next trade alert for free, right here.
